Moderna and Merck Present Phase 3 Melanoma Data on Oct. 24. Here Is What to Look For in the Numbers.
INTerpath-001 tests the individualized mRNA therapy intismeran autogene plus pembrolizumab in 1,137 patients with resected stage IIB to IV melanoma. The August topline release gave no hazard ratios; full data come at 10:30 a.m. Eastern on Oct. 24.
Merck and Moderna will present the first detailed Phase 3 results for intismeran autogene, their individualized mRNA neoantigen therapy, with pembrolizumab in resected melanoma at 10:30 a.m. Eastern on Saturday, Oct. 24, at the ESMO Congress in Madrid.
Until now the public record has been an Aug. 19 topline announcement with no effect sizes. The presentation should show how large the recurrence benefit is, how long patients have been followed and what the combination adds in toxicity.
When and where is the presentation?
INTerpath-001 is late-breaking abstract LBA1 in the Presidential Symposium of the European Society for Medical Oncology congress, according to Moderna’s Sept. 21 announcement. The session is at 4:30 p.m. Central European Summer Time, or 10:30 a.m. Eastern, with Georgina V. Long of Sydney presenting. The congress runs Oct. 23 to 27, and Moderna will host an investor webcast at 1 p.m. Eastern the same day.
What do we know already?
On Aug. 19, the companies said the combination met its primary endpoint, recurrence-free survival, and its key secondary endpoint, distant metastasis-free survival, compared with pembrolizumab alone at a prespecified interim analysis, The ASCO Post reported. The randomized, double-blind, placebo- and active-comparator-controlled trial enrolled 1,137 patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma and no prior systemic therapy, assigned 2:1. As CancerNetwork described the design, patients receive pembrolizumab 400 mg with either intismeran 1 mg or placebo. The safety profile was consistent with earlier studies, with no new safety signals observed.
Hazard ratios, absolute event rates and P values were not disclosed, Practical Dermatology reported, and overall survival is still being evaluated. The trial's ClinicalTrials.gov record, sponsored by Merck, lists an estimated primary completion date of October 2029.
A positive interim analysis tells you the direction. The hazard ratio, its confidence interval and the follow-up time tell you whether to change what you tell patients.
What did the earlier trial show?
The randomized Phase 2b KEYNOTE-942 trial, in a five-year update presented at the 2026 American Society of Clinical Oncology meeting, reported a recurrence-free survival hazard ratio of 0.51 (95 percent confidence interval, 0.294 to 0.887) and a distant metastasis-free survival hazard ratio of 0.411 (95 percent CI, 0.200 to 0.843) versus pembrolizumab alone, according to CancerNetwork. The intervals are wide. Phase 3 is designed to pin down the size of the effect.
Moderna chief executive Stéphane Bancel called the Phase 3 findings "a pivotal moment for the field of cancer research" in the topline release, as quoted by Practical Dermatology. Long, the trial's principal investigator, said the combination "has the potential to establish a new treatment paradigm in the adjuvant melanoma setting," The ASCO Post reported. Dean Y. Li, president of Merck Research Laboratories, said, as quoted by CancerNetwork, that the results "reinforce the promise of a more personalized approach to cancer treatment."
What should you look for in the data?
Five details will matter most. The first is the recurrence-free survival hazard ratio and its interval, with median follow-up. The second is the distant metastasis-free survival result, which speaks to the harder outcome. The third is results by stage, since the population spans IIB to IV. The fourth is immune-related adverse events and discontinuations against pembrolizumab alone. The fifth is whatever overall survival data exist at this cut.
Is the therapy approved?
No. Moderna describes intismeran autogene as investigational. In August the companies said the data would be presented at a medical meeting and "shared with regulatory authorities," according to The ASCO Post, which reported no filing timeline.
What it means in clinic
Nothing changes for patients today. Pembrolizumab is the current standard-of-care immunotherapy in the adjuvant setting for resected melanoma, CancerNetwork noted, and it is the comparator in this trial. If patients ask about a "melanoma vaccine," the accurate answer this week is that it is an individualized mRNA therapy given with pembrolizumab, with full Phase 3 results due Oct. 24 and no approval yet.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
